Search results
Results from the WOW.Com Content Network
Two Advanced Cryogenic Evolved Stage (ACES) concepts were originally developed in 2005 by both Boeing and Lockheed Martin. [4] [5] [clarification needed]By 2010, ULA had inherited the intellectual property of both proposals, and the ACES concept had evolved into a new high-performance upper stage to be used on both Atlas V and Delta IV/Delta IV Heavy launch vehicles.
The agreement guaranteed that Allergan has license to the patents at an annual royalty rate of $15 million per year in addition to an up-front charge that amounted to $13.75 million. [5] This was a landmark deal, as never before had a Native American tribe been given full ownership of a patent by way of a major American corporation.
The broad program announcement for ACE was published on June 30, 2010. [4] ACE funded the Aggregative Contingent Estimation System (ACES) website and interface on July 15, 2011. [5] They funded The Good Judgment Project some time around July 2011. [6] ACE has been covered in The Washington Post'' [7] and Wired Magazine. [8]
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.
The development of ACES II began in early 1990 in the group of Professor Rodney J. Bartlett at the Quantum Theory Project (QTP) of the University of Florida in Gainesville. There, the need for more efficient codes had been realized and the idea of writing an entirely new program package emerged.
Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. [ 2 ]
Zeltiq Aesthetics is a subsidiary of AbbVie based in Pleasanton, California that markets and licenses devices used for cryolipolysis procedures. The company was founded in 2005 and raised $75 million in funding before going public in 2011.
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...